Update on risankizumab for the treatment of moderate to severe psoriasis-Reference-Cited by-同舟云学术

Update on risankizumab for the treatment of moderate to severe psoriasis

Published:2020-09-25 Issue:11 Volume:20 Page:1245-1251
ISSN:1471-2598
Container-title:Expert Opinion on Biological Therapy
language:en
Short-container-title:Expert Opinion on Biological Therapy

Author:

Al-Janabi A¹^ORCID,Warren RB¹

Affiliation:

1. The Dermatology Centre, Salford Royal NHS Foundation Trust, Manchester NIHR Biomedical Research Centre, Manchester Academic Health Science Centre, The University of Manchester, Salford, UK

Funder

not funded

Publisher

Informa UK Limited

Subject

Clinical Biochemistry,Drug Discovery,Pharmacology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14712598.2020.1822813

Reference55 articles.

1. Tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: long-term safety and efficacy in an open-label extension study

2. A randomized phase 2b trial of baricitinib, an oral Janus kinase ( JAK ) 1/JAK2 inhibitor, in patients with moderate‐to‐severe psoriasis

3. Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis

4. https://clinicaltrials.gov/ct2/show/NCT03881059

5. Systemic Treatment of Psoriasis with JAK Inhibitors: A Review

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-Term Safety of Risankizumab in Patients with Psoriatic Disease: A Comprehensive Analysis from Clinical Trials;Dermatology and Therapy;2024-08-17

2. Reappraising the Use of Systemic Immunomodulators for Psoriasis and Eczema in the Military;Military Medicine;2024-04-11

3. Psoriasis and Related Disorders;Rook's Textbook of Dermatology;2024-03-19

4. Actualización práctica de las recomendaciones del Grupo de Psoriasis de la Academia Española de Dermatología y Venereología (GPS) para el tratamiento de la psoriasis con terapia biológica. Parte 2 «Manejo de poblaciones especiales, pacientes con comorbilidad y gestión del riesgo»;Actas Dermo-Sifiliográficas;2022-06

5. [Translated article] Practical Update of the Guidelines Published by the Psoriasis Group of the Spanish Academy of Dermatology and Venereology (GPs) on the Treatment of Psoriasis With Biologic Agents: Part 2—Management of Special Populations, Patients With Comorbid Conditions, and Risk;Actas Dermo-Sifiliográficas;2022-06